Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

Phase 1

Completed

Conditions: Vaginal Cancer
Cervical Cancer
Endometrial Cancer
Radiation Toxicity

Interventions: Other: survey administration
Other: computer-assisted intervention
Behavioral: telephone-based intervention

Brief Summary: This randomized, pilot phase I trial studies whether phone or email reminders increases vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they undergo brachytherapy. Brachytherapy is a type of internal radiation which uses radioactive material placed directly into or near a tumor to kill tumor cells. A reminder program may help increase use of vaginal dilators and decrease long-term side effects following brachytherapy.

Detailed Description: PRIMARY OBJECTIVES:

I. Evaluate whether vaginal dilator adherence is improved with additional reminder phone calls and/or email reminder survey.

SECONDARY OBJECTIVES:

I. Evaluate whether there are differences in the length of vaginal canal between the non-intervention and intervention groups. Evaluate rates of gynecologic, urinary, and gastrointestinal toxicity.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive no additional reminders.

ARM II: Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.

ARM III: Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.

After completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months, 11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment.

Recruitment & Eligibility

Inclusion Criteria

Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment
Patients cannot have previously received pelvic external beam radiation or brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy radiation treatment.
Patients should have a life expectancy of at least 1 year
No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status requirements
No organ and marrow function requirements
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
No restrictions regarding use of other investigational agents
No exclusion requirements due to co-morbid disease or intercurrent illness
No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device
No exclusion criteria relating to concomitant medications
No exclusion criteria for pregnant or nursing patients from participating in this study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a requirement for enrolling on this study)

Arm && Interventions

Group	Intervention	Description
Arm III (email surveys and phone calls)	survey administration	Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
Arm II (email survey)	survey administration	Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
Arm II (email survey)	computer-assisted intervention	Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
Arm III (email surveys and phone calls)	computer-assisted intervention	Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
Arm III (email surveys and phone calls)	telephone-based intervention	Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.

Primary Outcome Measures

Name	Time	Method
Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation	Up to 25 months after completing radiation	The vaginal dilator adherence measurements will analyzed in repeated measures model with treatment as a fixed effect and time as a within subject effect. The overall mean of vaginal dilator adherence among the 3 groups will also be measured and compared. The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.

Secondary Outcome Measures

Name	Time	Method
Vaginal canal length	Up to 25 months after completing radiation	The vaginal canal length will be measured using an extra small dilator and it will be calculated in centimeters. The vaginal canal length measurements will be analyzed in a repeated measures model with treatment as a fixed effect and time as a within subject effect. The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.
Incidence of adverse events (AE), reported by type and grade using the Common Terminology Criteria for Adverse Events version 4.03	Up to 30 days after the last dose of study treatment	The adverse events will be tabulated by type and grade at each follow up. The total number of AE's as well as the number of AE's in each category: gynecologic, urinary and gastrointestinal will tabulated. The test of proportion will be done per category of AE. Since it is possible that the rates will be low, an exact test will be used to compare the rates.

Locations (1): Stanford University, School of Medicine
🇺🇸
Stanford, California, United States